Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
2024 pubmed

[A new way for the differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in adolescent men aged 13.5-17 years].

Skorodok. Y L YL; Ioffe. I Y IY; Plotnikova. E V EV; Nagornaya. I I II; Zhelenina. L A LA; Kozhevnikova. A V AV

Key Findings

  • A hormone‑based score reliably separates hypogonadotropic hypogonadism from constitutional delay of puberty in boys aged 13.5‑17.
  • Score <21.16 predicts constitutional delay; score ≥55.07 predicts hypogonadotropic hypogonadism; intermediate scores need extra testing.
  • The scoring system achieved about 97% accuracy in a validation group.

Practical Outcomes

  • This work is a clinical diagnostic tool for adolescent males and offers no direct protocol or dosage guidance for biohackers. Triptorelin is used only as a test agent, not as a supplement for longevity, metabolic health, or performance.

Summary

Researchers made a simple scoring system that looks at four hormone levels (LH, FSH, testosterone, inhibin B) to tell whether a teenage boy’s delayed puberty is due to a medical problem (hypogonadotropic hypogonadism) or just a normal late start (constitutional delay). They used a drug called triptorelin to help confirm the diagnosis, but the method is meant for doctors treating adolescents, not for self‑experiments or performance enhancement.

Abstract

Differential diagnosis of hypogonadotropic hypogonadism (HH) and constitutional delay of puberty (CDP) is extremely important since with the latter puberty begins and completes without any medical intervention and in the case of HH puberty does not occur or is incomplete. Failure to start treatment on time leads to medical and psychosocial maladjustment of the patient. Development of a method for differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in boys 13.5-17 years old by scoring the levels of LH, FSH, testosterone and inhibin B. The study group was formed by adolescent men 13.5-17 years old with delayed puberty including all observations. Anamnesis, stage of puberty, testicular volume were assessed; serum levels of LH, FSH, testosterone (T) were determined by chemiluminescent analysis and inhibin B, AMH by ELISA. Stimulation tests were performed with triptorelin and human chorionic gonadotropin (3 days). Patients were followed up for 6-24 months. The study included adolescent men at the age of 13.5-17 years with delayed puberty: 56 for the purpose of development a method of differential diagnosis, 30 for its control (control group). We`ve created a method that allows differentiate HH and CDP. Through the ROC-analysis the most sensitive and specific HH markers were identified. The basal levels of LH, FSH, T, and inhibin B were selected as most available for outpatient testing. Based on the results of our own research and scientific data we selected ranges of values and rated LH, FSH, T and inhibin B depending on them (marks). Then we assigned the coefficients (k) for each hormone. Scores were calculated by multiplying the marks by k then summed and normalized to the maximum amount the patient could get. To increase the accuracy of diagnosis an age coefficient was introduced. The result of the calculation was the result of the scoring (S). S for CDP (10.65 [3.13-14.91]) differed significantly from that for HH (76.46 [57.79-83.74]) (p&amp;lt; 0.001). Diagnoses based on S (&amp;lt;21.16 and &#x2265;55.07) in the&#xa0;control group were confirmed by follow up data in 97% cases. An algorithm for the differential diagnosis of HH and CDP by using S has been developed. The result of scoring of LH, FSH, testosterone, inhibin B levels &#x2265;55.07 makes it possible to diagnose hypogonadotropic hypogonadism, &amp;lt; 21.16 - constitutional delay of puberty with a high probability. In the case of score &#x2265;21.16 but &amp;lt; 55.07, calculation of the inhibin B/AMH ratio and/or stimulation tests are required.

Study Information

Provider

pubmed

Year

2024

Date

2024-03-09T00:00:00.000Z

DOI

10.14341/probl13419

References

16